Priscilla K. Brastianos, MD, of Massachusetts General Hospital, discusses genomic characterization of brain metastases and paired primary tumors, which could reveal potential therapeutic targets (Abstract 2905).
Federico Cappuzzo, MD, of Istituto Toscano Tumori-Ospedale Civile Livorno, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss current strategies for treating patients with acquired resistance, and what the future holds for these patients.
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discusses this prospective study of endocrine therapy alone in patients with ER-positive, HER2-negative, node-negative breast cancer (Abstract 5BA).
Jean-Yves Douillard, MD, PhD, of Centre R Gauducheau, reviews new clinical trials and data on systemic and radiation treatment of small cell lung cancer.
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, and ECCO President, discusses ways in which imaging can form the solution to individualized cancer treatment.
Lisa Carey, MD, of the University of North Carolina, discusses heterogeneity, treatment response, and outcome in HER2-positive breast cancer.
